Phase 2, Multicenter, Open-Label Study of CS-1008, A Humanized Monoclonal antibody targeting death receptor 5 (DR) in combination with gemcitabine in chemotherapy naive subjects with unresectable or metastatic pancreatic cancer
|Effective start/end date||8/14/07 → 8/31/10|
- ICON CLINICAL RESEARCH, INC
- SANKYO CO LTD
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.